Track topics on Twitter Track topics that are important to you
Redx Pharma Plc (LON:RDX) is expected to exit administration after selling its Bruton’s tyrosine kinase (BTK) inhibitor technology and drug development programme for US$40mln. The deal was struck on Friday with NASDAQ-listed Loxo Oncology Inc (NASDAQ:LOXO). The company was developing a treatment of leukaemia and Redx’s BTK was to be one of the second-generation of compounds with fewer side-effects than the market leader Imbruvica (often referred to as Ibrutinib). Importantly, the company’s drug was targeted at overcoming resistance that patients have developed to the current gold standard treatment. The transaction, which could also see Redx relisted on AIM, follows a rocky period for the life sciences group. Its shares were suspended in May after it entered administration when Liverpool Council called in a £2mln loan. Jason Baker, joint administrator of the company, said the sale of part of Redx portfolio was represented a “significant step forward” for business and its rescue as going concern. “Today's unconditional agreement is for the realisation of certain of the group's intellectual property assets, the proceeds from which will allow for the creditors of the companies to be paid in full and provide working capital for the group's continuing business, thus restoring the companies to solvency,” he explained. “The administrators anticipate that, upon their review and approval of the management's final business plan, the company will be set to exit administration. “Upon exit from administration the directors of the company will be in a position to request the lifting of the suspension of the company's shares from trading on AIM. “Until the exit from administration we shall continue with the discharge of our statutory duties as administrators in the interests of all creditors."
Original Article: Redx Pharma set to exit administration after US$40mln saleNEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...